title: Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer.
abstract: Although at present, there is a high incidence of prostate cancer, particularly in the Western world, mortality from this disease is declining and occurs primarily only from clinically significant late stage tumors with a poor prognosis. A major current focus of this field is the identification of new biomarkers which can detect earlier, and more effectively, clinically significant tumors from those deemed "low risk", as well as predict the prognostic course of a particular cancer. This strategy can in turn offer novel avenues for targeted therapies. The large family of Receptor Tyrosine Kinases, the Ephs, and their binding partners, the ephrins, has been implicated in many cancers of epithelial origin through stimulation of oncogenic transformation, tumor angiogenesis, and promotion of increased cell survival, invasion and migration. They also show promise as both biomarkers of diagnostic and prognostic value and as targeted therapies in cancer. This review will briefly discuss the complex roles and biological mechanisms of action of these receptors and ligands and, with regard to prostate cancer, highlight their potential as biomarkers for both diagnosis and prognosis, their application as imaging agents, and current approaches to assessing them as therapeutic targets. This review demonstrates the need for future studies into those particular family members that will prove helpful in understanding the biology and potential as targets for treatment of prostate cancer.
authors: Institute of Health and Biomedical Innovation, Queensland University of Technology, Queensland, Australia. j.lisle@qut.edu.au
authors: Jessica E
authors: JE
authors: Lisle
authors: Inga
authors: I
authors: Mertens-Walker
authors: Raphael
authors: R
authors: Rutkowski
authors: Adrian C
authors: AC
authors: Herington
authors: Sally-Anne
authors: SA
authors: Stephenson
mesh_terms: D015415:Biomarkers; D036342:Ephrins / Q000032:analysis / Q000502:physiology*; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000209:etiology; D036082:Receptor, EphA1 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D015398:Signal Transduction
chemical_list: D015415:Biomarkers; D036342:Ephrins; D036082:Receptor, EphA1